InterMune Inc. Fourth Quarter Earnings Sneak Peek

InterMune, Inc. (NASDAQ:ITMN) will unveil its latest earnings on Thursday, February 9, 2012. InterMune is a biotech company, which is focused on developing and commercializing innovative therapies in pulmonology and hepatology.

InterMune, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for a loss of 71 cents per share, a wider loss from the year earlier quarter net loss of 39 cents. During the past three months, the average estimate has moved up from a loss of 72 cents. Between one and three months ago, the average estimate moved down. It has risen from a loss of 73 cents during the last month.

Last quarter, the company came in at net loss of 63 cents per share against a mean estimate of a loss of 73 cents per share, beating estimates after missing them in the previous quarter. In the second quarter, it missed forecasts by 7 cents.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: On average, analysts predict $7.9 million in revenue this quarter, a decline of 96.7% from the year ago quarter. Analysts are forecasting total revenue of $25.7 million for the year, a decline of 90.1% from last year’s revenue of $259.3 million.

Analyst Ratings: Analysts are bullish on this stock with 13 analysts rating it as a buy, one rating it as a sell and one rating it as a hold.

A Look Back: In the third quarter, the company’s loss widened to a loss of a $38.2 million (63 cents a share) from a loss of $24.3 million (44 cents) a year earlier, but beat analyst expectations. Revenue fell 7.5% to $5.2 million from $5.7 million.

Key Stats:

A year-over-year revenue decrease in the third quarter snapped a streak of three consecutive quarters of revenue increases. Revenue rose 5.9%in the second quarter, 4.4% in the first quarter and 3555.5% in the fourth quarter of the last fiscal year.

Stock Price Performance: During November 7, 2011 to February 3, 2012, the stock price had fallen $7.18 (-31%) from $23.18 to $16. The stock price saw one of its best stretches over the last year between February 9, 2011 and February 16, 2011 when shares rose for six-straight days, rising 5.2% (+$1.89) over that span. It saw one of its worst periods between November 11, 2011 and November 21, 2011 when shares fell for seven-straight days, falling 16% (-$3.43) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Don’t Miss These Additional Hot Stories:

These Retailers Continue to Confuse Investors

Are You Ready for Some Super Bowl Inflation?

Is 2012 the Year of the Golden Dragon?

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at